02/19/2025 5:25 PM | Arbutus Biopharma (Issuer) Sims Karen (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/19/2025 5:25 PM | Arbutus Biopharma (Issuer) HASTINGS DAVID C (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/19/2025 5:25 PM | Arbutus Biopharma (Issuer) McElhaugh Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/19/2025 5:25 PM | Arbutus Biopharma (Issuer) Naftzger J. Christopher (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/04/2025 7:34 PM | Arbutus Biopharma (Subject) Naftzger J. Christopher (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025 7:36 PM | Arbutus Biopharma (Subject) McElhaugh Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025 7:38 PM | Arbutus Biopharma (Subject) Sims Karen (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025 7:39 PM | Arbutus Biopharma (Subject) HASTINGS DAVID C (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/03/2025 2:26 PM | Arbutus Biopharma (Subject) MORGAN STANLEY (Filed by)
| Form SCHEDULE 13G/A | |
01/13/2025 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/05/2024 11:15 PM | Arbutus Biopharma (Filer)
| Form EFFECT | |
Get the Latest News and Ratings for ABUS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.
|
11/15/2024 10:03 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/14/2024 7:41 AM | Arbutus Biopharma (Subject) Two Seas Capital LP (Filed by)
| Form SC 13G/A | |
11/06/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/15/2024 7:26 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/11/2024 3:07 PM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/01/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/10/2024 3:50 PM | Arbutus Biopharma (Subject) MORGAN STANLEY (Filed by)
| Form SC 13G | |
06/06/2024 10:16 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/05/2024 5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/28/2024 3:25 PM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/24/2024 3:07 PM | Arbutus Biopharma (Issuer) Torti Frank (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/22/2024 5:00 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/17/2024 8:03 AM | Arbutus Biopharma (Subject) Whitefort Capital Management, LP (Filed by)
| Form SC 13D/A | |
05/09/2024 7:00 AM | Arbutus Biopharma (Subject) Whitefort Capital Management, LP (Filed by)
| Form SC 13D | |
05/02/2024 3:32 PM | Arbutus Biopharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/02/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/02/2024 6:26 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/10/2024 3:05 PM | Arbutus Biopharma (Filer)
| Form DEF 14A | |
04/10/2024 3:06 PM | Arbutus Biopharma (Filer)
| Form DEFA14A | |
04/04/2024 7:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/29/2024 6:31 AM | Arbutus Biopharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |